Table 1 Baseline demographics and patient characteristics, in patients who underwent or not a post-procedural major adverse event
|  | All patients (n = 160) | MAE− (n = 124) | MAE+ (n = 36) | p value |
|---|---|---|---|---|
Age (years)a | 84 [80–88] | 84 [81–88] | 84 [79–87] | 0.56 |
Male | 79 (49) | 60 (48) | 19 (53) | 0.64 |
Comorbidities | ||||
 Smoking | 21 (13) | 15 (12) | 6 (17) | 0.57 |
 Dyslipidemia | 77 (48) | 61 (49) | 16 (44) | 0.62 |
 Diabetes mellitus | 41 (26) | 32 (26) | 9 (25) | 1.00 |
 Hypertension | 119 (74) | 89 (72) | 30 (83) | 0.16 |
 Obesity (BMI ≥ 30 kg m−2) | 25 (16) | 23 (19) | 2 (6) | 0.07 |
 COPD | 119 (74) | 94 (76) | 25 (69) | 0.44 |
 Stroke | 23 (14) | 18 (15) | 5 (14) | 1.00 |
 Peripheral artery disease | 22 (14) | 16 (13) | 6 (17) | 0.59 |
Coronary artery disease | 100 (62) | 79 (64) | 21 (58) | 0.56 |
Medications | ||||
 Beta-blockers | 27 (17) | 22 (18) | 5 (14) | 0.62 |
 ECA | 55 (34) | 42 (34) | 13 (36) | 0.94 |
 Statin | 69 (43) | 55 (44) | 14 (39) | 0.39 |
 Aspirin | 71 (44) | 55 (44) | 16 (44) | 0.82 |
 Clopidogrel | 47 (29) | 37 (30) | 10 (28) | 0.83 |
 Biguanides | 9 (6) | 9 (7) | 0 (0) | 0.12 |
 Insulin | 8 (5) | 6 (5) | 2 (6) | 1.00 |
Previous CABG | 38 (24) | 30 (24) | 8 (22) | 1.00 |
NYHA class III or IV | 95 (59) | 69 (56) | 26 (72) | 0.07 |
Pacemaker | 23 (14) | 16 (13) | 7 (19) | 0.42 |
Atrial fibrillation | 38 (24) | 31 (25) | 7 (19) | 0.66 |
Logistic Euroscore (%)a | 20 [12–32] | 20 [12–30] | 26 [14–36] | 0.09 |
Baseline eGFR (ml min−1 1.72 m−2)a | 42 [30–58] | 42 [29–60] | 40 [30–46] | 0.21 |
Preoperative blood glucose level (mmol l−1)a | 5.3 [4.7–6.1] | 5.3 [4.6–6.1] | 5.2 [4.9–5.7] | 0.83 |
Glycosylated hemoglobin (%)a | 6.0 [5.5–6.8] | 6.0 [5.5–6.8] | 5.8 [5.5–6.5] | 0.55 |
Left ventricular function | 0.60 | |||
 Good (LVEF ≥ 50%) | 108 (68) | 86 (70) | 22 (61) |  |
 Fair (LVEF 30–49%) | 47 (29) | 34 (27) | 13 (36) |  |
 Poor (LVEF < 30%) | 5 (3) | 4 (3) | 1 (3) |  |
Mean transaortic gradient (mm Hg)a | 49 [40–57] | 49 [42–57] | 46 [35–57] | 0.40 |